# iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626

> **NCT03810898** · EARLY_PHASE1 · TERMINATED · sponsor: **CHDI Foundation, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **RADIATION:** Radioligand [¹¹C]CHDI-00485180-R
- **RADIATION:** Radioligand [¹¹C]CHDI-00485626

## Key facts

- **NCT ID:** NCT03810898
- **Lead sponsor:** CHDI Foundation, Inc.
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-09
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Study terminated per protocol design post interim analysis review after Phase 2a. No SAEs or safety issues were noted.
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03810898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03810898, "iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03810898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*